Literature DB >> 2646183

Tissue expression of CA 125 in benign and malignant lesions of ovary and fallopian tube: a comparison with CA 19-9 and CEA.

W Neunteufel1, G Breitenecker.   

Abstract

Sections of formalin-fixed and paraffin-embedded tissue specimens of 11 normal ovaries and tubes, 13 tubo-ovarian abscesses, 3 tubal carcinomas, and 115 ovarian tumors were investigated by immunohistochemistry. CA 125 and CA 19-9 were demonstrated with monoclonal antibodies, CEA with polyclonal antibodies. The tissue expression was visualized by the avidin-biotin method. In the germinal epithelium of all ovaries no tumor marker was confirmed. In 4 out of 11 tubes the epithelium was CA 125 positive, in 2 out of 11 cases CA 19-9 positive. Nine out of 13 tubo-ovarian abscesses were CA 125 and 5 out of 13 were CA 19-9 positive in their epithelium. Elevated serum levels of these markers might be due to expression via the epithelial cell of the inflamed tube. All normal and inflammatory adnexal tissues were CEA negative. In serous tumors and undifferentiated carcinomas, CA 125 was most frequently confirmed (85 and 70%, respectively). All mucinous tumors were CA 125 negative. The most frequently confirmed tumor marker was CA 19-9 (77%). In endometrioid tumors, CEA was most frequent (44%). In 42% of the borderline tumors and carcinomas only one marker was demonstrated, in 7% none. Here, immunohistochemistry may indicate the most adequate marker. Tumor marker expression was markedly heterogenous: tumor areas with strong, weak, and no reaction were adjacent. The tumor markers revealed no specificity for malignancy or disease.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2646183     DOI: 10.1016/0090-8258(89)90628-8

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  10 in total

Review 1.  Primary fallopian tube cancer: a review of the literature.

Authors:  A C Hellström
Journal:  Med Oncol       Date:  1998-04       Impact factor: 3.064

2.  Immunohistochemical differentiation between ovarian granulosa cell tumors and ovarian carcinomas.

Authors:  G Gitsch; P Kohlberger; E Hanzal; H Kölbl; G Breitenecker
Journal:  Arch Gynecol Obstet       Date:  1991       Impact factor: 2.344

3.  Immunohistochemical characterization of undifferentiated carcinomas of the ovary.

Authors:  Y Kuwashima; T Uehara; K Kishi; K Shiromizu; M Matsuzawa; S Takayama
Journal:  J Cancer Res Clin Oncol       Date:  1994       Impact factor: 4.553

4.  The detection, treatment, and biology of epithelial ovarian cancer.

Authors:  Jennifer Aa Gubbels; Nick Claussen; Arvinder K Kapur; Joseph P Connor; Manish S Patankar
Journal:  J Ovarian Res       Date:  2010-03-29       Impact factor: 4.234

5.  Influence of tumor grade on expression of CA 125 in serum and tissue in patients with serous ovarian carcinoma.

Authors:  Igor But
Journal:  Wien Klin Wochenschr       Date:  2003-04-30       Impact factor: 1.704

6.  The differential diagnosis of primary peritoneal papillary tumors.

Authors:  G Gitsch; U Tabery; W Feigl; G Breitenecker
Journal:  Arch Gynecol Obstet       Date:  1992       Impact factor: 2.344

7.  Clinical characteristics of genital chlamydia infection in pelvic inflammatory disease.

Authors:  Sung Taek Park; Suk Woo Lee; Min Jeong Kim; Young Mo Kang; Hye Min Moon; Chae Chun Rhim
Journal:  BMC Womens Health       Date:  2017-01-13       Impact factor: 2.809

8.  Phosphoproteomics of Primary Cells Reveals Druggable Kinase Signatures in Ovarian Cancer.

Authors:  Chiara Francavilla; Michela Lupia; Kalliopi Tsafou; Alessandra Villa; Katarzyna Kowalczyk; Rosa Rakownikow Jersie-Christensen; Giovanni Bertalot; Stefano Confalonieri; Søren Brunak; Lars J Jensen; Ugo Cavallaro; Jesper V Olsen
Journal:  Cell Rep       Date:  2017-03-28       Impact factor: 9.423

Review 9.  Primary mucinous ovarian tumors vs. ovarian metastases from gastrointestinal tract, pancreas and biliary tree: a review of current problematics.

Authors:  Pavel Dundr; Naveena Singh; Barbora Nožičková; Kristýna Němejcová; Michaela Bártů; Ivana Stružinská
Journal:  Diagn Pathol       Date:  2021-03-11       Impact factor: 2.644

10.  A Platform of Patient-Derived Microtumors Identifies Individual Treatment Responses and Therapeutic Vulnerabilities in Ovarian Cancer.

Authors:  Nicole Anderle; André Koch; Berthold Gierke; Anna-Lena Keller; Annette Staebler; Andreas Hartkopf; Sara Y Brucker; Michael Pawlak; Katja Schenke-Layland; Christian Schmees
Journal:  Cancers (Basel)       Date:  2022-06-12       Impact factor: 6.575

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.